1463 related articles for article (PubMed ID: 28940194)
21. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
22. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels.
Hendriks BS; Opresko LK; Wiley HS; Lauffenburger D
J Biol Chem; 2003 Jun; 278(26):23343-51. PubMed ID: 12686539
[TBL] [Abstract][Full Text] [Related]
23. β-Heregulin impairs EGF induced PLC-γ1 signalling in human breast cancer cells.
Rommerswinkel N; Keil S; Adawy A; Hengstler JG; Niggemann B; Zänker KS; Dittmar T
Cell Signal; 2018 Dec; 52():23-34. PubMed ID: 30165102
[TBL] [Abstract][Full Text] [Related]
24. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.
Collier TS; Diraviyam K; Monsey J; Shen W; Sept D; Bose R
J Biol Chem; 2013 Aug; 288(35):25254-25264. PubMed ID: 23843458
[TBL] [Abstract][Full Text] [Related]
25. Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling.
Menezes SV; Sahni S; Kovacevic Z; Richardson DR
J Biol Chem; 2017 Aug; 292(31):12772-12782. PubMed ID: 28615452
[TBL] [Abstract][Full Text] [Related]
26. A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion.
Rao VH; Kandel A; Lynch D; Pena Z; Marwaha N; Deng C; Watson P; Hansen LA
Oncogene; 2012 Jun; 31(23):2888-98. PubMed ID: 21986939
[TBL] [Abstract][Full Text] [Related]
27. Targeting the HER3 pseudokinase domain with small molecule inhibitors.
Colomba A; Claus J; Gao F; George R; Fornili A; Cameron AJM
Methods Enzymol; 2022; 667():455-505. PubMed ID: 35525551
[TBL] [Abstract][Full Text] [Related]
28. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
Monsey J; Shen W; Schlesinger P; Bose R
J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
[TBL] [Abstract][Full Text] [Related]
29. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
[TBL] [Abstract][Full Text] [Related]
30. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.
Muthuswamy SK; Gilman M; Brugge JS
Mol Cell Biol; 1999 Oct; 19(10):6845-57. PubMed ID: 10490623
[TBL] [Abstract][Full Text] [Related]
31. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer.
Krähn G; Leiter U; Kaskel P; Udart M; Utikal J; Bezold G; Peter RU
Eur J Cancer; 2001 Jan; 37(2):251-9. PubMed ID: 11166154
[TBL] [Abstract][Full Text] [Related]
32. Myofibroblasts have an impact on expression, dimerization and signaling of different ErbB receptors in OSCC cells.
Büttner R; Berndt A; Valkova C; Richter P; Korn A; Kosan C; Liebmann C
J Recept Signal Transduct Res; 2017 Feb; 37(1):25-37. PubMed ID: 27051967
[TBL] [Abstract][Full Text] [Related]
33. Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells.
Hendriks BS; Orr G; Wells A; Wiley HS; Lauffenburger DA
J Biol Chem; 2005 Feb; 280(7):6157-69. PubMed ID: 15572377
[TBL] [Abstract][Full Text] [Related]
34. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma.
Elebro J; Heby M; Warfvinge CF; Nodin B; Eberhard J; Jirström K
PLoS One; 2016; 11(4):e0153533. PubMed ID: 27070783
[TBL] [Abstract][Full Text] [Related]
35. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of the expression of EGFR signaling pathway-related proteins in esophageal squamous cell carcinoma.
Li JC; Zhao YH; Wang XY; Yang Y; Pan DL; Qiu ZD; Su Y; Pan JJ
Tumour Biol; 2014 Jan; 35(1):651-7. PubMed ID: 24052437
[TBL] [Abstract][Full Text] [Related]
37. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
38. Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression.
Zhang Y; Gonzalez RM; Zangar RC
BMC Cancer; 2011 Feb; 11():69. PubMed ID: 21320340
[TBL] [Abstract][Full Text] [Related]
39. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
[TBL] [Abstract][Full Text] [Related]
40. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
